Cited by 16Tissue Engineering and Regenerative MedicineXenotransplantation and immune responseOrgan and Tissue Transplantation Research

In Vitro Detection System to Evaluate the Immunogenic Potential of Xenografts

Daugs, Aila, Lehmann, Nadine, Eroglu, Dilem, Meinke, Martina C., Markhoff, Annina, Bloch, Oliver·2018·Tissue Engineering Part C: Methods

Abstract

Tissue antigenicity represents the main limitation for the use of xenografts in clinical practice. To eliminate xenoantigens and avoid graft rejection in human, decellularization is often used to remove all immunoreactive components from the extracellular matrix (ECM). After decellularization, acellular scaffolds are required to be investigated regarding the presence of antigens, but commonly used detection methods solely focus on known xenoantigens such as alpha Gal (Galα1,3-Galβ1-4GlcNAc-R) or major histocompatibility complex-I (MHC-I). However, there are unknown xenoantigens that escape the standard methods. To evaluate the immunological potential of xenogenic tissues, new in vitro methods need to be developed. Therefore, we established a novel human serum-based approach, including dot blot, Western blot, immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). With these methods, we analyzed protein extracts and tissue samples of native and decellularized bovine carotid arteries. All methods verified an effective removal of potential immunogens from the ECM through decellularization, and relative quantification with ELISA showed that 99.9% (p < 0.01) of antigenic components were successfully eliminated. We compared our human serum-based methods with commonly used assays for the detection of alpha Gal and MHC-I. Our results showed highly increased sensitivity for xenoantigens using the human serum antibody pool. This novel in vitro detection system allows the direct determination of the immunogenic potential of xenografts and is a vast improvement in comparison to the methods used so far. That way, it is possible to optimize the decellularization process to prevent hyperacute graft rejection in patients.

Integrity signals

Registry

Crossref · 10.1089/ten.tec.2017.0532

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Interspecies variations between ECM components such as collagen, laminin, fibronectin, elastin, and growth factors are not extreme, making xenogeneic ECM plausible surrogates for their human-derived counterparts.

    “Interspecies variations between ECM components such as collagen, laminin, fibronectin, elastin, and growth factors are not extreme, making xenogeneic ECM plausible surrogates for their human-derived counterparts [114, 117–119].”
  • Despite efficacy of GA treatment in decreasing hyperacute and acute rejection of xenogeneic tissues, GA crosslinking does not fully inactivate antigenic sites, and grafts would still be susceptible to delayed immune recognition and chronic rejection.

    “Despite the efficacy of GA treatment in decreasing hyperacute and acute rejection of xenogeneic tissues, GA crosslinking does not fully inactivate antigenic sites, and grafts would still be susceptible to delayed immune recognition and chronic rejection [117, 200].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Daugs, A., Lehmann, N., Eroglu, D., Meinke, M. C., Markhoff, A., & Bloch, O.
Affiliations
  • Auto Tissue Berlin GmbH, Berlin, Germany.
  • Charité – Universitätsmedizin Berlin (DE)
Corresponding author
Daugs, Aila
Venue
Tissue Engineering Part C: Methods
Published
2018-05
Volume
24
Issue
5
Pages
280-288
ISSN
  • 1937-3384 (ISSN-L)
  • 1937-3392
OpenAlex
W2793818596
Cited by
16
References
66
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 1
FWCI
1.57
Type
journal article
Language
en
Open access
closed
Locations
  • Tissue Engineering Part C Methods (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bundesministerium für Wirtschaft und Energie
  • Johnson and Johnson
Topics
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Health Sciences › Medicine › Surgery › Xenotransplantation and immune response
  • Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
Keywords
decellularization, xenoantigens, acellular scaffolds, extracellular matrix, alpha-galactosides, MHC class I, graft rejection, hyperacute rejection
MeSH terms
Animals, Carotid Arteries, Cattle, Cells, Cultured, Humans, Reference Standards, Endothelial Cells, Serum, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review